AI Cuts Drug Discovery From Years to Months
I joined Sam Fazeli for the latest episode of Bloomberg Intelligence's Vanguards of Healthcare podcast and talk about our partnership with Eli Lilly and why I believe algorithmic approaches are reshaping the earliest stages of pharmaceutical R&D. The biggest impact is in speed: processes that used to take years can now be compressed into months, especially in the preclinical stage. We discuss the recent deal and what it signals for the industry. Smaller biotech companies can now compete in ways that were previously difficult to imagine, moving faster, operating leaner, and innovating alongside large pharmaceutical companies and ambitious global players. This is not just about doing the same science faster. It is about changing the structure, economics, and methodology of how new medicines are discovered. Apple Podcasts: https://t.co/ZjE8mTrGdr Spotify: https://t.co/UTuzW9NAMF #EliLilly #GenerativeAI #DrugDiscovery #Biotech #Pharma #AI #InsilicoMedicine
Telehealth Gets Discounted GLP‑1 Service, Outsmarts Weightwatchers
GLP-1 as a service and at a massive discount. Entire distribution now massively and exclusively advantaging telehealth providers. Of course Mr efficient thinks that’s a nothing burger for Weightwatchers. Can’t make this up https://t.co/62IYen2o3b
Regulators Lag as AI Accelerates Drug Discovery
AI in drug discovery is moving faster than any other sector right now. Eli Lilly. Computational pharma. FDA timelines under pressure. The bottleneck isn't the AI. It's whether regulatory frameworks were designed for a world where drug candidates get identified in months.
Viral Research Reveals Immune Secrets for Vaccine Design
Here is my talk on how studying viral infections can teach us a lot about the immune system, and how we can use those insights to develop vaccines against viruses. "Night science moments" make science so exciting 🌓 @NightScienceIns @ItaiYanai...
FDA Standards Threaten Affordable Academic Gene Therapies
The scientists behind treating Baby KJ say the FDA is imposing standards that could make it too expensive for them — or any academics — to bring such bespoke therapies to approval. https://t.co/OrxMXBVev4
FDA Hurdles Stall Academic Scaling of Custom Gene Editor
Baby KJ scientists hit speed bump in quest to scale custom gene editor. Stringent FDA requirements could prove stumbling block for academics https://t.co/HsaK7lSuh1 via @Jasonmmast
US VCs Embed in Chinese Labs, Courting Scientists Early
U.S. venture capital firms are no longer waiting for Chinese biotech assets to surface before investing in them — they’re moving upstream, embedding themselves inside labs and courting scientists before they publish their research https://t.co/7kOlGh0sbu
Enhanced Games Could Deliver Credible Data for Peptide Legitimacy
Data, data, data... The @enhanced_games are so much more than just another sports event... "The peptide community has a credibility problem and an evidence problem. Millions of people use compounds backed by rodent studies and Reddit threads. The FDA is cracking...
Hype Undermines Science, Fuels Unfounded Doubt
"This kind of hype is dangerous. It undermines more serious science and brings into play doubt about data that’s yet to be presented.” https://t.co/43glXqCyx9
Mental‑health Biotech Will Outgrow Disease‑focused Pharma
Consumer biotech and pharma will ultimately be a much bigger business than sickness-focused biotech and pharma. And what people crave even more than being sexy is being happy. Hence, I believe #mentalhealth will be the largest subsector and companies like my @ataibeckley...
Telomir's IND Filing Sparks Speculative Long On
Telomir filed IND for oral Telomir‑1 in TNBC. Data: clean GLP safety; Phase1/2 planned. Risk: pre‑revenue, weak balance sheet, stock -65%. Trade: speculative long on IND clearance. — Viktor Kopylov, PhD, CFA. More insights: t.me/si14Kopylov
Diabetes Drug Empagliflozin Shows Promise for Early Alzheimer’s
As a medical school professor, I've long suspected that Alzheimer's disease is metabolic at its core. Now we have clinical proof. A Wake Forest trial tested empagliflozin -- a common diabetes drug -- in NON-DIABETIC Alzheimer's patients for the first time. The...
Eli Lilly Acquires Centessa for $7.8B in Neuro Push
Lilly buying $CNTA Centessa (hub & spoke R&D co) for $6.3B + $1.5B CVR. Another neuro deal. Big congrats to @Medicxi, Index ventures, General Atlantic https://t.co/jkC9dv6d3I @medicx
Biogen Buys Apellis for $5.6B, Adds SYFOVRE Sales‑linked CVR
1/Another mega M&A deal in the BioTech and Pharma sector with the acquisition of Apellis Pharmaceuticals - $APLS by Biogen $BIIB for $41 per share in cash at closing in a $5.6B deal. In addition, Apellis stockholders will also receive...
Genetic-Level Solutions Needed; Dyno Tackles Untreatable Diseases
Eric Kelsic said: "To address the root cause of a genetic disease, you need to take action at the genetic level." But this isn’t possible today. If you have sickle cell, Huntington's or cystic fibrosis, there's no cure for you just yet. Here's...
Predicting Late‑Stage Trial Outcomes Could Speed Drug Development
Accurately predicting success and failure rate of late stage trials for new drugs could legitimately accelerate pharma. The late stages are where most of the time and money go, and are a bottleneck on bringing drugs to market today.
Prediction Claims 100% Success for MLTX in Psoriatic Arthritis
Really interesting. One of their predictions is 100% success chance for $MLTX in psoriatic arthritis.
Peptides Shift From Biomarkers to Feeling Control, Raising Risks
I think peptides are popular because they give people a feeling of power and control. One feels helpless when they can't sleep, stop scrolling, eat well or exercise consistently. A few injections wrestles back a feeling of control. Evidence...
Setidegrasib’s KRAS Degradation Still Unproven in Cancer
Elegant in theory, unproven in practice: setidegrasib and the case (or not) for KRAS degradation in NSCLC and pancreatic cancer: https://t.co/NuaOJ2amgn https://t.co/i9FpK4W19W
Lilly‑InsilicoMeds Partnership Grows to $2.75 B
30March: How did @EliLillyandCo and @InSilicoMeds begin and expand their collaboration into the up-to-$2.75B partnership announced Sunday? Read about $LLY and $3696 in the latest for @GENbio from me and colleague @xiaofei_lin: https://t.co/KtXOWFjGdq
LQDA's Superior Delivery Threatens UTHR's Orphan Edge
The $UTHR news today is great for IPF patients. But it is also very good news for $LQDA given they have better delivery of the same drug. UTHR has 7-year orphan protection in IPF, but that can be overcome by...
Your Trial Recruitment Fails at the Website Front Door
Everyone complains that clinical trial recruitment is hard. Fair. 📍 But here is a question not enough people ask: Have you looked closely at your 𝘁𝗿𝗶𝗮𝗹 𝗿𝗲𝗰𝗿𝘂𝗶𝘁𝗺𝗲𝗻𝘁 𝘀𝗶𝘁𝗲? I ran one through https://t.co/f9IW600hsB. The science was solid. The 𝗺𝗲𝘀𝘀𝗮𝗴𝗶𝗻𝗴 𝘄𝗮𝘀 𝗻𝗼𝘁. 📉 That is the disconnect. Too...
Key FDA Decisions Shaping Biotech Q2 2026
New: 5 FDA decisions to watch in the second quarter of 2026 https://t.co/AVvu8i9kgh $REPL $LLY $AXSM $PFE $ARVN $IONS $ARWR #biotech
R3 Bio's Push for Brainless Human Clones Sparks Ethical Debate
Here's our story about R3 Bio and the entrepreneur dreaming of brainless human clones. https://t.co/ZJpdffTKNP
IMMX Completes NEXICART‑2 Enrollment, Paving Path
$IMMX hits a big milestone: NEXICART-2 enrollment complete BLA-enabling Strong prior efficacy (~75% CR) No approved therapies in R/R AL https://t.co/0iUBMaSetC
Beware: Longevity Tourism Sells Unproven, Risky Therapies
“Longevity tourism” Plenty of folks willing to travel & pay for “stem cells as magical thinking” and a growing panoply of unproven & sometimes dangerous “#longevity” therapies. Caveat emptor. By @PeterWardJourno in @Slate https://t.co/jq9rPrcRK2
Gates Foundation Funds TesseraTx's Gene‑editing HIV Cure Research
1/🚨@TesseraTx has announced that it has received a grant from the Gates Foundation to fund an early-stage research which is aimed to develop a Gene Editing-based cure for HIV. This grant is build upon Tessera’s existing investment 🧵👇 from the Gates...
Graphene Oxide Selectively Kills Bacteria, Spares Humans
Graphene oxide targets and destroys bacterial membranes by binding to a unique lipid absent in human cells, enabling selective antibacterial action and offering a promising alternative to conventional antibiotics. nanotechnology
Stopping Alzheimer’s Drugs Speeds Decline, Raises Death Risk
Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study https://t.co/YUcSc7w9HG
Modulating RNA Folding Boosts Drug Efficacy More than Binding
Small molecules that alter RNA structure, rather than simply binding to it, have a greater impact on RNA function, highlighting the importance of targeting RNA folding in drug development. molecularbiology
Network Pharmacology Reveals Natural Products' Neuroprotective Power
Network pharmacology approach to unravel the neuroprotective potential of natural products: a narrative review https://t.co/LGgQeHQHwF https://t.co/OiCYu2OxZq
MRK's Sotatercept Shows Inverse Dose Response in 6
$TENX $TECX 🤔 $MRK sotatercept high dose *missed* stat sig on 6MWT in P2 (and it wasn’t particularly close). The low dose hit stat sig (barely) and was the dose taken to P3. What to make of a...
GLP‑1 Drugs Now Help Psoriatic Arthritis Beyond Weight Loss
The list of conditions for which GLP-1 drugs provide benefit independent of weight loss keeps growing. Add psoriatic arthritis #AAD26 @AADskin https://t.co/kJej6osXTS
SGLT2 Inhibitors Help HFrEF Mice via Off‑Target Effects
SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice “The beneficial effects of SGLT2i treatment in gKO mice conclusively demonstrate that in a physiologically relevant preclinical model of HFrEF, SGLT2i can exert therapeutic benefits via off-target pharmacology.3...
Intranasal 5-MeO-DMT Boosts Depression Relief with SSRIs
The results of this first phase 2a clinical trial of intranasal 5-MeO-DMT administered adjunctively to SSRIs demonstrated acceptable safety and tolerability with promising improvements in depressive symptoms. https://t.co/m15DkPP4qX
FDA Greenlights Viagra: A Pivotal HealthTech Milestone
#ThisDayInTechHistory. March 27, 1998. The FDA approved Viagra developed by Pfizer. (Untold Story) #HealthTech #JVGpost https://t.co/GJea9vd0v9
FDA Confirms Myocarditis Risk, Validating Parents' COVID Concerns
Great thread and one addition: Increased risk of myocarditis in young boys. The demonization of parents who asked, the denials by healthcare professionals and bureaucrats, and ultimately, the admission and subsequent FDA warning proving parents worst fears correct. It will take...
Psilocybin Emerges as Promising Longevity Therapy
When I started Don't Die in 2021, we evaluated all the scientific evidence for the most powerful anti-aging therapies. Psychedelics were no where to be found. A wild turn of events that they're now front and center for us....
PCSK9 Inhibitor Cuts Cardiovascular Events in Diabetics
In a randomized trial of a PCSK9 inhibitor [for LDL cholesterol lowering] vs placebo for patients with diabetes and no known heart disease, there was significant reduction of major cardiovascular events including deaths #ACC26 @JAMA_current https://t.co/mzuI79c4IN https://t.co/16Cpxf7IBx
Intensive LDL < 55 Mg/dL Cuts Cardiovascular Events
Validation of aggressive LDL lowering to reduce major adverse cardiovascular events, a randomized trial targeting LDL < 55 mg/dl. In participants with atherosclerotic cardiovascular disease (secondary prevention) @NEJM #ACC26 https://t.co/oLnkqhawOd
AI Meets Scalable Single-Cell Data, Transforming Medicine
AI needs data. And biology is finally generating it at scale. I spoke with @10xGenomics CEO Serge Saxonov about the single-cell and spatial biology revolution — and why the convergence of AI + biological measurement could transform medicine. Read the full profile...
Combining Modest Therapies Unlocks Big Benefits, Reduces Waste
Adam, I used to think this way. Then gene therapy & IO worked. IL2 has consumed a lot of hope; but new variations make it hard to quit. Abeta worked. And synergy: combine modest drugs, unlock big benefits. Invest or...
Retatrutide's Sales Potential Tempered by Heart Risks
I'm fairly sure retatrutide will be the largest peak-sales drug in history (inflation-adjusted). My lingering question is the resting HR elevation of ~5–7 bpm and a 4–14% arrhythmia rate (vs. 2–3% placebo) seen in Phase 2 data, plus insomnia reported...
New Atlas Maps All Human E3 Ligases, Unifying Research
A comprehensive atlas now defines all human E3 ligases, resolving decades of inconsistencies and providing a unified framework to advance research and therapeutic development for diseases linked to these essential enzymes. biotechnology
First Earnings Call Unveils AI‑Driven Aging Therapies
Our first ever earnings call coming up tomorrow - we are reporting our 2025 annual results. I will start the call with the 5 minute introduction to AI drug discovery and how we measure AI drug discovery productivity. In my...
GLP‑1 Drugs Could Help Prevent Cancer, Study Shows
As a medical school professor, I've watched GLP-1 drugs transform diabetes and obesity treatment. Now a Nature Cancer review reveals they may suppress cancer too. GLP-1 drugs reduce insulin resistance, lower inflammation, and cut body weight -- three of the biggest...
Weight‑loss Drugs Curb Intake; Future Targets Calorie Burn
The current meds help people eat fewer calories. That’s how they work for weight loss (yes they have weight independent effects like CVD reduction). The next frontier is helping burn more calories.
Oral GLP‑1 Battle Heats up Amid FDA Uncertainty
Oral GLP-1 wars, FDA drift, HIV franchise defense, and a few biotech landmines | Ep. 970 https://t.co/sx4kBXzgSL [ 02:30 ] oral GLP-1 battlefield heats up [ 03:08 ] convenience factor drives adoption [ 04:51 ] tolerability issues hit persistence [ 05:45 ] Novo writes $2.1...
Β‑Hydroxybutyrate's Dual Impact on Colorectal Cancer
β-Hydroxybutyrate, a primary metabolite of ketogenic diets and its dual role in modulating colorectal cancer: from molecular mechanisms to therapeutic insights https://t.co/pPCdm2AcFo https://t.co/mPtz1Xqiep
Earendil Labs Secures $787M to Accelerate AI Biologics
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development Who is winning AI race again? https://t.co/ZW4S2zUGkS